A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Tositumomab; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
    • 12 Jun 2013 Planned End Date changed from 1 Jun 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Planned end date changed from 1 Oct 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top